Nivolumab + ipilimumab more effective in immunotherapy-resistant melanoma than ipilimumab alone

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation awarded a $1 million grant to support research at Vanderbilt aimed at dramatically expanding the efficacy of immunotherapy for colorectal cancer.

October 04, 2024

Vol.50 No.37

Regulatory News

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.

September 27, 2024

Vol.50 No.36

Regulatory News

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation

A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Follow-up data from the phase IIb randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with Keytruda in patients with resected high-risk melanoma (stage 3/4) following complete resection.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Ten-year follow-up data shows Opdivo + Yervoy improves OS in advanced melanoma

Ten-year follow-up data from CheckMate-067, a randomized, double-blind, phase III clinical trial showed continued durable improvement in survival with first-line Opdivo (nivolumab) plus Yervoy (ipilimumab) therapy and Opdivo monotherapy, versus Yervoy alone, in patients with previously untreated advanced or metastatic melanoma.

September 20, 2024

Vol.50 No.35

Nivolumab + ipilimumab more effective in immunotherapy-resistant melanoma than ipilimumab alone

YOU MAY BE INTERESTED IN

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Ten-year follow-up data shows Opdivo + Yervoy improves OS in advanced melanoma

Renew today!

Subscriber content

Login

Nivolumab + ipilimumab more effective in immunotherapy-resistant melanoma than ipilimumab alone

YOU MAY BE INTERESTED IN

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitorsVote applies across drugs and indications

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover designThe agency accepts the invitation

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Ten-year follow-up data shows Opdivo + Yervoy improves OS in advanced melanoma

Login

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation